Sglt2 Inhibitor

Leading experts from multiple specialties will once again convene to address the relationship between type 2 diabetes, cardiovascular and renal disease along with the latest research demonstrating their interconnectedness.

Eight professional societies issued a joint report on the dangers associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, calling on clinicians to work together across specialties and align treatment strategies.

In 1989, the FDA’s approval of Epogen – epoetin alfa manufactured by Amgen Inc. – offered patients with kidney disease an opportunity to break away from blood transfusions, the washout after dialysis and improve their quality of life.

In April, the FDA approved use of dapagliflozin (Farxiga, AstraZeneca)to reduce the risk for kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.

The dual SGLT1/SGLT2 inhibitor sotagliflozin is effective at reducing risk for heart failure, myocardial infarction and stroke while also slowing progression of chronic kidney disease, according to findings from two large clinical trials.

In this video exclusive, Richard E. Pratley, MD, talks with Deepak L. Bhatt, MD, MPH, about results and implications of the SOLOIST and SCORED trials of the SGLT1/SGLT2 inhibitor sotogliflozin vs. placebo in adults with type 2 diabetes.

The SGLT2 inhibitor dapagliflozin is well-tolerated in adults hospitalized with COVID-19, regardless of diabetes status, according to new analyses from the DARE-19 trial.

In this video exclusive, Richard E. Pratley, MD, talks with Mikhail Kosiborod, MD, FACC, FAHA, about the DARE-19 trial, which explored repurposing existing medications to treat COVID-19.

For Jens J. Holst, MD, DMSc, there were long years spent “in the desert” studying how incretin hormones in the gut work before he and his team would go on to discover the peptide that would change type 2 diabetes and obesity management.